Simulated driving performance in healthy adults after night‐time administration of 20 mg tasimelteon

An impairment in next day driving performance has been reported for almost every drug currently United States Food and Drug Administration (FDA) approved for improvement of sleep in chronic and transient insomnia. Tasimelteon, a melatonin receptor agonist, demonstrated significant improvements in ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Rosarelis, Fisher, Michaela, Birznieks, Gunther, Polymeropoulos, Christos, Kay, Gary G., Xiao, Changfu, Polymeropoulos, Mihael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285441/
https://www.ncbi.nlm.nih.gov/pubmed/34152055
http://dx.doi.org/10.1111/jsr.13430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285441/
https://www.ncbi.nlm.nih.gov/pubmed/34152055
http://dx.doi.org/10.1111/jsr.13430

Ejemplares similares